Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men
- PMID: 1279225
- DOI: 10.1016/s0022-5347(17)37041-6
Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men
Abstract
We investigated the value of digital rectal examination, transrectal ultrasonography and prostatic specific antigen (PSA) analysis as aids in general clinical practice and in the early detection of prostate cancer. Of a randomly selected population of 2,400 men 55 to 70 years old who were offered examination with digital rectal examination, transrectal ultrasound and PSA analysis, 1,782 (74%) accepted and prostate cancer was detected in 65 (3.6%). When the transrectal ultrasound results were also considered the detection rate of digital rectal examination (2.3%) was increased by 50% and the number of stage T2A or less tumors was doubled. At reexamination due to markedly high PSA values (7 micrograms/l. or more) only a few additional cancers (5%) were detected. However, it is noteworthy that 80% of the detected cancers were found among the subgroup with abnormal PSA values (4 micrograms/l. or more) and comprising 17% of the study population, which suggests the possibility of selecting a risk group at mass screening. Moreover, the positive predictive value increased from 4% (when only digital rectal examination was positive) to 71% for the combination of positive digital rectal examination, positive transrectal ultrasound and an increased PSA concentration (that is 7 micrograms/l. or greater).
Similar articles
-
Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.J Urol. 1994 May;151(5):1283-90. doi: 10.1016/s0022-5347(17)35233-3. J Urol. 1994. PMID: 7512659 Clinical Trial.
-
Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.J Urol. 2017 Feb;197(2S):S200-S207. doi: 10.1016/j.juro.2016.10.073. Epub 2016 Dec 22. J Urol. 2017. PMID: 28012755 Clinical Trial.
-
Prostate cancer detection at low prostate specific antigen.J Urol. 2000 Mar;163(3):806-12. J Urol. 2000. PMID: 10687982 Clinical Trial.
-
Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.J Urol. 1996 Nov;156(5):1685-90. J Urol. 1996. PMID: 8863571 Review.
-
Elevated prostate-specific antigen, abnormal prostate evaluation on digital rectal examination, and transrectal ultrasound and prostate biopsy.Urol Clin North Am. 1998 Nov;25(4):581-9, viii. doi: 10.1016/s0094-0143(05)70049-5. Urol Clin North Am. 1998. PMID: 10026767 Review.
Cited by
-
Prostate-specific antigen testing accuracy in community practice.BMC Fam Pract. 2002 Oct 24;3:19. doi: 10.1186/1471-2296-3-19. Epub 2002 Oct 24. BMC Fam Pract. 2002. PMID: 12398793 Free PMC article.
-
Prostate cancer, screening, and prostate-specific antigen: promise or peril?J Gen Intern Med. 1994 Aug;9(8):468-74. doi: 10.1007/BF02599070. J Gen Intern Med. 1994. PMID: 7525903 Review. No abstract available.
-
Screening for prostate cancer.Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Cochrane Database Syst Rev. 2013. PMID: 23440794 Free PMC article.
-
Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer.Prostate. 2022 Jun;82(8):911-916. doi: 10.1002/pros.24335. Epub 2022 Mar 16. Prostate. 2022. PMID: 35294068 Free PMC article.
-
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.Int J Clin Oncol. 2024 May;29(5):512-534. doi: 10.1007/s10147-024-02497-0. Epub 2024 Mar 17. Int J Clin Oncol. 2024. PMID: 38493447
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous